GlassScriptPhysician profile
Shawn A Seibert
NPI 1437166717
$4,653.51
in general payments reported to CMS, 2019-2025
28 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $28.63 · 2021: $592 · 2022: $351 · 2023: $444 · 2024: $796 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Consulting Fee: $1,001 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.81 |
| Consulting Fee | $1,001.25 |
| Education | $207.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,097.80 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $759.02 | 2023-2025 | Imfinzi, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $682.53 | 2021-2025 | Keytruda, Lynparza, Lenvima |
| Organogenesis INC. | $439.92 | 2019-2021 | |
| Janssen Biotech, INC. | $304.83 | 2022-2025 | Rybrevant, Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.38 | 2022 | |
| Abbvie INC. | $151.15 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $122.39 | 2021 | |
| Glaxosmithkline, LLC. | $102.83 | 2023 | Zejula |
| Smith+Nephew, INC. | $82.52 | 2019-2023 | Acticoat 4" X 4", Pico 7 |
| Tempus Ai, INC | $81.04 | 2024 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Tosoh Bioscience, INC. | $48.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47.30 | 2021-2022 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $42.02 | 2023-2025 | Ultomiris |
| Emd Serono, INC. | $41.57 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $35.58 | 2025 | |
| Myriad Genetic Laboratories, INC. | $22.40 | 2021 | |
| Celularity INC. | $20.00 | 2019 | |
| Convatec INC. | $17.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2020 | |
| Janssen Scientific Affairs, LLC | $14.38 | 2025 | Tecvayli |
| Aroa Biosurgery Incorporated | $14.15 | 2019 | |
| Tactile Systems Technology INC | $12.06 | 2020 | |
| Misonix INC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Seibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.